



REFERENCES

- ¹Langsjoen P, Langsjoen A. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10 A review of animal and human publications. *Biofactors*. 2003;18:101-11.
- ²Rundek T, Naini A, Sacco R et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. *Arch Neurol*. 2004;61:889-892.
- ³Pacanowski M, Frye R, Enogieru O et al. Plasma coenzyme Q10 predicts lipid-lowering response to high-dose atorvastatin. *J Clin Lipidol* 2008;2:289-297.
- ⁴Brown, Michael. Coenzyme Q.sub.10 with HMG-CoA reductase inhibitors. Patent 4,933,165. 12 June 1990.
- ⁵Banach M, Serban C, Ursoniu S et al. Statin therapy and plasma coenzyme Q10 concentrations-A systematic review and meta-analysis of placebo-controlled trials. *Pharmacol Res*. 2015;99:329-336.
- ⁶La Guardia P, Alberici L, Ravagnani F et al. Protection of rat skeletal muscle fibers by either L-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation. *Front Physiol* 2013;4:103.
- ⁷Galvano F, Li Volti G, Malaguarnera M et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. *Expert Opin Pharmacother* 2009;10:1875-1882.
- ⁸Shojaei M, Djalali M, Khatami M et al. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. *Iran J Kidney Dis*. 2011;5:114-118.
- ⁹Bhuiyan J, Seccombe DW. The effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit. *Lipids*. 1996;3:867-870.
- ¹⁰Kupetsky-Rincon EA, Uitto J. Magnesium: novel applications in cardiovascular disease--a review of the literature. *Ann Nutr Metab*. 2012;61:102-110.
- ¹¹Rosanoff A, Seelig MS. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. *J Am Coll Nutr*. 2004;23:501S-505S.
- ¹²Saito N, Nishiyama S. Aging and magnesium. *Clin Calcium*. 2005;15:29-36.
- ¹³Brown B, Zhao X, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med*. 2001;345:1583-1592.
- ¹⁴Shehadah A, Chen J, Cui X et al. Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome. *J Neurol Sci*. 2010;294):107-111.
- ¹⁵Julius U. Niacin as antidiabetic drug. *Can J Physiol Pharmacol*. 2015:1-12. [Epub ahead of print]
- ¹⁶Villines TC, Kim AS, Gore RS et al. Niacin: the evidence, clinical use, and future directions. *Curr Atheroscler Rep*. 2012;14:49-59.
- ¹⁷Goldie C, Taylor AJ, Nguyen P et al. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. *Heart*. 2015; [Epub ahead of print]
- ¹⁸Ghaypur-Mobarhan M, Lamb D, Taylor A et al. Effect of statin therapy on serum trace element status in dyslipidaemic subjects. *J Trace Elem Med Biol*. 2005;19:61-67.
- ¹⁹Fowler D, Cooper S, Stephany J et al. Suppression of statin effectiveness by copper and zinc in yeast and human cells. *Mol Biosyst*. 2011;7:533-544.
- ²⁰Costarelli L, Muti E, Malavolta M et al. Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors. *Rejuvenation Res*. 2008;11:287-291.
- ²¹Suchy-Dicey A, Heckbert S, Smith N et al. Gene expression in thiazide diuretic or statin users in relation to incident type 2 diabetes. *Int J Mol Epidemiol Genet*. 2014;17;5:22-30.
- ²²Okuyama H, Langsjoen P, Hamazaki T et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. *Expert Rev Clin Pharmacol*. 2015;8:189-199.
- ²³Nakazato R, Gransar H, Berman DS et al. Statins use and coronary artery plaque composition: results from the International Multicenter CONFIRM Registry. *Atherosclerosis*. 2012;225:148-153.
- ²⁴Gast GC, de Roos NM, Sluijs I et al. A high menaquinone intake reduces the incidence of coronary heart disease. *Nutr Metab Cardiovasc Dis*. 2009;19:504-510.
- ²⁵Palaniswamy C, Sekhri A, Aronow WS et al. Association of warfarin use with valvular and vascular calcification: a review. *Clin Cardiol*. 2011;34:74-81.
- ²⁶Galli F, Iuliano L. Do statins cause myopathy by lowering vitamin E levels? *Med Hypotheses*. 2010;74:707-709.
- ²⁷Sinzinger H. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK elevation? *Atherosclerosis* 2000;149:225.
- ²⁸Parker R., Pearce B, Clark R et al, Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *J Biol Chem*. 1993;268:11230-11238.
- ²⁹Houston M, Fazio S, Chilton F et al. Nonpharmacologic treatment of dyslipidemia. *Prog Cardiovasc Dis*. 2009;52:61-94.
- ³⁰Moosman B, Behl C. Selenoprotein synthesis and side-effects of statins. *Lancet* 2004;363:892-894.
- ³¹Moosman, Behl C. Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway. *Trends Cardiovasc Med*. 2004;14:273-281.
- ³²Fuhrmeister J, Tews M, Kromer A et al. Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells. *Toxicol Lett*. 2012;215:219-227.
- ³³Ahmed W, Khan N, Glueck C et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. *Transl Res* 2009;153:11-16.
- ³⁴Glueck C, Budhani S, Masimeni S et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. *Curr Med Res Opin*. 2011;27:1683-1690.
- ³⁵Resolution of statin-induced myalgias by correcting vitamin D deficiency. *South Med* 2010;103:690-692.
- ³⁶Mergenhagen K, Ott M, Heckman K et al. Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review. *Clin Ther*. 2014;36:770-777.

This material is for informational and educational purposes only, and is not intended to constitute or substitute for the advice of a physician or other healthcare professional. Specific diagnosis, treatment plans, and interpretations, should be provided and reviewed by the treating practitioner.

© 2018 SpectraCell Laboratories, Inc. All rights reserved. Doc 362 4.18



Additional references at <http://www.spectracell.com/online-library-mnt-adhd-abstracts/>